At a glance
- HempStreet Medicare was pursuing Brazil entry for Formulation Femme under ANVISA RDC 660.
- Formulaite produced a Simulaite mechanistic evidence layer while the clinical study was already underway.
- The simulation treated the formulation as a polyherbal system, covering the cannabinoid load and Ayurvedic adaptogen components together.
- The product moved into the Brazilian market through Entourage Phytolab under CEO Caio Abreu.
The challenge
HempStreet Medicare, founded by Abhishek Mohan, was advancing Formulation Femme, a low-dose non-psychotropic cannabinoid formulation for primary dysmenorrhea, through a regulated international pathway. The clinical trial supporting the ANVISA submission was already underway before Formulaite engaged.
The team needed a mechanistic view of how the full formulation behaved in vivo: not only the cannabinoid component, and not only a single surrogate active, but the cannabinoid and Ayurvedic adaptogen chemistry together.
How Formulaite worked with HempStreet
Formulaite ran a polyherbal simulation in Simulaite across the full Formulation Femme composition. The model represented the formulation as administered, including cannabinoid load and Ayurvedic adaptogens, rather than flattening the product into a single-active pharmacokinetic proxy.
The detailed simulation output is proprietary to HempStreet. The shareable result is that HempStreet received a mechanistic evidence layer that helped explain how the formulation could support the intended dysmenorrhea program while staying within the non-psychotropic exposure profile it was designed around.
Clinical trial product format
The tablet format is the Formulation Femme product format that moved through clinical trials in India.
Why it mattered
For regulated phytotherapeutic and cannabinoid products, a clinical result is stronger when the sponsor can explain the mechanism behind it. Formulaite helped HempStreet connect the clinical and regulatory story to a formulation-level scientific rationale that regulators, prescribers, and commercial partners can understand.
The case established a repeatable pattern for Formulaite: mechanistic simulation can work alongside active clinical programs in regulated phytopharmaceutical markets, especially where polyherbal chemistry is central to the product.
What to know
HempStreet's clinical, regulatory, and Brazil distribution work created the pathway for Formulation Femme. Formulaite added the mechanistic evidence layer that helped the team explain the full formulation with more scientific confidence.